Caroline Robert, MD, PhD; Sandrine Faivre; Eric Raymond; Jean-Pierre Armand; Bernard Escudier
Potential Financial Conflicts of Interest: None disclosed.
Robert C, Faivre S, Raymond E, Armand J, Escudier B. Subungual Splinter Hemorrhages: A Clinical Window to Inhibition of Vascular Endothelial Growth Factor Receptors?. Ann Intern Med. 2005;143:313-314. doi: 10.7326/0003-4819-143-4-200508160-00021
Download citation file:
Published: Ann Intern Med. 2005;143(4):313-314.
TO THE EDITOR:
Background: Over the past few years, cancer therapy has been profoundly changed by the development of drugs targeting specific kinases involved in the proliferation of tumor or endothelial cells. Some kinase inhibitors exhibit antiangiogenic activity by targeting vascular endothelial growth factor receptors (VEGFRs).
Objective: We report the results of tests of 2 such inhibitors: SU11248 (Pfizer, New York, New York), which inhibits VEGFR-2, platelet-derived growth factor receptor (PDGFR), KIT, and flt3, and BAY 439006 (Onyx Pharmaceuticals, Emeryville, California, and Bayer, Leverkusen, Germany), which targets VEGFR-2 and VEGFR-3, PDGFR, and RAF gene products.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only